Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Antiviral Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå : 1684493
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 188 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÁÖ¿ä ÀλçÀÌÆ®

Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå - º¸°í¼­ ¹üÀ§

Ç×¹ÙÀÌ·¯½ºÁ¦´Â ¼÷ÁÖ ³»¿¡¼­ ¹ÙÀÌ·¯½º º¹Á¦¸¦ ¾ïÁ¦ÇÏ¿© ¹ÙÀÌ·¯½º °¨¿°À» Ä¡·áÇϵµ·Ï ¼³°èµÈ ¾à¹°ÀÔ´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦´Â ÀÎÇ÷翣ÀÚ, HIV, °£¿°, COVID-19¿Í °°Àº Áúº´À» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ À¯º´·ü Áõ°¡¿Í ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀ¸·Î Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦ÀÇ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº º´¿ø, Áø·á¼Ò, ¿¬±¸±â°ü, Á¦¾àȸ»ç¿¡ ´ëÀÀÇÏ¿© ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ë¿ä¹ý ¹× ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¼¼°è Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖÀ¸¸ç, HIV, BÇü °£¿°, CÇü °£¿°°ú °°Àº ¸¸¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀº Ç×¹ÙÀÌ·¯½ºÁ¦ °³¹ßÀÇ ½Ã±ÞÇÑ Çʿ伺À» °­Á¶ÇÏ¸ç ¿¬±¸¿Í ±â¼ú Çõ½ÅÀÇ °¡¼ÓÈ­¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Áö¼ÓÇü ÁÖ»çÁ¦ ¹× ³ª³ë±â¼ú ±â¹Ý ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ Ç×¹ÙÀÌ·¯½º ¾à¹° Á¦ÇüÀÇ ¹ßÀüÀº Ä¡·á È¿°ú¿Í ȯÀÚ ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×¹ÙÀÌ·¯½ºÁ¦ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú ÀÚ±Ý Áö¿ø, Á¦¾à»çµé °£ÀÇ Àü·«Àû Á¦ÈÞ°¡ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ

Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀº À¯¸ÁÇÑ ¼ºÀå¼¼¿¡µµ ºÒ±¸ÇÏ°í ³ôÀº ¿¬±¸°³¹ß(R&D) ºñ¿ë°ú ¸Å¿ì ±ä ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ÀýÂ÷¶ó´Â µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾àÁ¦ ³»¼º ¹ÙÀÌ·¯½º ±ÕÁÖÀÇ ÃâÇöµµ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ¾àÁ¦ °³¼±°ú »õ·Î¿î Ä¡·á Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â Ç×¹ÙÀÌ·¯½ºÁ¦¿¡ ´ëÇÑ Á¢±Ù¼º ¹× °¡¿ë¼ºÀÌ Á¦ÇѵǾî ÀÖ¾î ½ÃÀå ħÅõ°¡ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦ °ü·Ã ºÎÀÛ¿ë°ú °ÅºÎ¹ÝÀÀµµ ȯÀÚ ¼øÀÀµµ ¹× Ä¡·á °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀº ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ½Å¾à°³¹ßÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î Å« ¼ºÀå ±âȸ¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ¿©·¯ ¹ÙÀÌ·¯½º¸¦ Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ´Â ±¤¹üÀ§ÇÑ Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ °³¹ßÀº ½ÃÀå È®´ëÀÇ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, AI¿Í ¸Ó½Å·¯´×À» Ȱ¿ëÇÑ ½Å¾à°³¹ßÀÌ Áõ°¡Çϸ鼭 »õ·Î¿î Ç×¹ÙÀÌ·¯½º È­ÇÕ¹° ¹ß±¼ÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Ç×¹ÙÀÌ·¯½º ¾à¹°°ú ¸é¿ª¿ä¹ý ¹× ´ÜŬ·ÐÇ×ü¿ÍÀÇ ÅëÇÕÀ¸·Î Ä¡·á È¿°ú°¡ Çâ»óµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÈï±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í °¨¿°¼º Áúȯ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀ» Á¶»çÇÏ¿© ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®

Á¦4Àå ¼¼°èÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦5Àå ¼¼°èÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á : Áö¿ª

Á¦6Àå ºÏ¹ÌÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦7Àå À¯·´ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ Àü¸Á(2019-2032³â)

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has recently published an in-depth analysis of the global antiviral drugs market, offering a detailed evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. The report provides exclusive data and statistical insights that highlight the expected growth trajectory of the antiviral drugs market from 2025 to 2032.

Key Insights:

Global Market Growth Rate (CAGR 2025 to 2032): 15.60%

Antiviral Drugs Market - Report Scope

Antiviral drugs are pharmaceutical agents designed to treat viral infections by inhibiting virus replication within the host. These drugs are essential in managing diseases such as influenza, HIV, hepatitis, and COVID-19. The increasing prevalence of viral infections, coupled with advancements in drug development, has significantly driven the demand for antiviral therapies. The market caters to hospitals, clinics, research institutions, and pharmaceutical companies, offering a wide range of treatment options. Additionally, the rising adoption of combination therapies and personalized medicine further propels market growth.

Market Growth Drivers

The global antiviral drugs market is expanding due to several key factors, including the rising incidence of viral diseases worldwide. The increasing burden of chronic viral infections such as HIV and hepatitis B & C is fueling demand for effective antiviral treatments. Moreover, the COVID-19 pandemic highlighted the urgent need for antiviral drug development, leading to accelerated research and innovation. Advancements in antiviral drug formulations, including long-acting injectables and nanotechnology-based drug delivery systems, are improving treatment efficacy and patient compliance. Furthermore, government initiatives and funding for antiviral drug research, along with strategic collaborations between pharmaceutical companies, are supporting market expansion.

Market Restraints

Despite its promising growth, the antiviral drugs market faces challenges such as high research and development (R&D) costs and lengthy regulatory approval processes. The emergence of drug-resistant viral strains poses a significant hurdle, necessitating continuous drug modifications and new treatment strategies. Additionally, limited accessibility and affordability of antiviral drugs in low- and middle-income countries restrict market penetration. Side effects and adverse reactions associated with antiviral medications also impact patient adherence and treatment outcomes.

Market Opportunities

The antiviral drugs market presents significant growth opportunities driven by ongoing advancements in biotechnology and drug discovery. The development of broad-spectrum antiviral drugs capable of targeting multiple viruses offers potential for market expansion. Additionally, the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery is accelerating the identification of novel antiviral compounds. The integration of antiviral drugs with immunotherapies and monoclonal antibodies is expected to enhance treatment effectiveness. Expanding healthcare infrastructure in emerging economies, coupled with rising investments in infectious disease research, will further drive market growth.

Key Questions Answered in the Report:

Competitive Intelligence and Business Strategy

Leading players in the global antiviral drugs market, including Gilead Sciences, GlaxoSmithKline, and Merck & Co., focus on continuous innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position. These companies invest heavily in R&D to develop next-generation antiviral therapies with enhanced efficacy and safety profiles. Collaborations with government agencies, research institutes, and biotech firms are accelerating drug discovery and development processes. Additionally, increased efforts in expanding global distribution networks and improving access to antiviral drugs in underserved regions are expected to drive long-term market growth.

Key Companies Profiled:

Antiviral Drugs Market Segmentation

By Drug Class

By Type

By Application

By Region

Table of Contents

1. Executive Summary

2. Market Overview

3. Value Added Insights

4. Global Antiviral Drugs Outlook, 2019-2032

5. Global Antiviral Drugs Market Outlook: Region

6. North America Antiviral Drugs Outlook, 2019-2032

7. Europe Antiviral Drugs Outlook, 2019-2032

8. East Asia Antiviral Drugs Outlook, 2019-2032

9. South Asia & Oceania Antiviral Drugs Outlook, 2019-2032

10. Latin America Antiviral Drugs Outlook, 2019-2032

11. Middle East & Africa Antiviral Drugs Outlook, 2019-2032

12. Competition Landscape

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â